US Stock MarketDetailed Quotes

XBIO Xenetic Biosciences

Watchlist
  • 4.0126
  • +0.0226+0.57%
Close Nov 21 16:00 ET
  • 4.0126
  • 0.00000.00%
Post 20:01 ET
6.19MMarket Cap-1508P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    12 hours ago
    Update
    $Xenetic Biosciences (XBIO.US)$ Xenetic Biosciences Presents Preclinical Data On DNase I Co-Administration With CAR T Cells, Highlighting Potential To Enhance Therapeutic Responses In Melanoma Lung Metastasis Model
    Benzinga· 9 mins ago
    Xenetic Biosciences Presents Preclinical Data On DNase I Co-Administration With CAR T Cells, Highlighting Potential To Enhance Therapeutic Responses In Melanoma Lung Metastasis Model
    Jaguar8
    Jaguar8
    12 hours ago
    NEWS
    $Xenetic Biosciences (XBIO.US)$
    Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
    Xenetic Biosciences (NASDAQ:XBIO)presented positive preclinical data showing the potential of co-administering DNase I with CAR T cells in treating melanoma lung metastasis. The study demonstrated that a single injection of DNase I (10 mg/kg) with EGFR-CAR T cells significantly sup...
    Jaguar8
    Jaguar8
    Nov 12 08:03
    NEWS
    $Xenetic Biosciences (XBIO.US)$
    Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
    Xenetic Biosciences (NASDAQ:XBIO)presented positive preclinical data demonstrating that DNase I significantly enhances the effectiveness of anti-CTLA-4 immune checkpoint blockade in colorectal carcinoma models. The study showed that systemic DNase I combined with α-CTLA-4 anti...
    Trytosaveabit
    Trytosaveabit
    Nov 7 08:13
    Update
    $Xenetic Biosciences (XBIO.US)$ Reuters· 3 mins ago
    Xenetic Biosciences - Advancing Dnase-Based Oncology Program Towards Clinical Proof-of-Concept Studies in Multiple Indications
    Jaguar8
    Jaguar8
    Nov 7 08:03
    NEWS
    $Xenetic Biosciences (XBIO.US)$
    Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
    Pure Oil & Gas, a subsidiary of Southern ITS International (OTC PINK:SITS), reports significant operational progress and secured $6 million in new funding for drilling projects. The company, managing 14 operating wells, has shown substantial monthly production increases from 175 barrels in June to an estimated 1,980 barrels in S...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data